erythromycin ethylsuccinate 40 MG/ML Oral Suspension [E.E.S.]

Drug interactions

Erythromycin has several clinically significant drug interactions, particularly with drugs metabolized by CYP3A4.

• majortheophylline — increased serum theophylline levels and potential toxicity
• majorverapamil — hypotension, bradyarrhythmias, and lactic acidosis
• moderatedigoxin — elevated digoxin serum levels
• moderateoral anticoagulants — increased anticoagulant effects
• majorergotamine/dihydroergotamine — acute ergot toxicity characterized by vasospasm and ischemia
• moderatetriazolam — increased pharmacologic effect
• majorHMG-CoA reductase inhibitors (e.g., lovastatin, simvastatin) — increased concentrations and potential rhabdomyolysis
• moderatesildenafil — increased systemic exposure (AUC)
• majorcisapride — QT prolongation, cardiac arrhythmias, and potential fatalities
• moderatecolchicine — significant increase in colchicine plasma concentration